Regulatory Considerations for the Treatment of Lipodystrophy – Roundtable Discussion - Forum for Collaborative HIV Research

Bill Powderly
University College Dublin
Ireland
Discussion areas

- Issues in design of clinical trials for treatment of HIV-associated lipodystrophy with regard to registration of a product for approval
  - Entry criteria
  - Monitoring issues
  - Response criteria
Conditions reviewed

- Facial lipoatrophy
- Peripheral lipoatrophy
- Visceral fat gain
- Dorsocervical fat pads
Facial lipoatrophy

- Entry criteria
  - Patient and physician defined
- Baseline measurement
  - Objective - ultrasound, photography
- Response criteria
  - Overall appearance improved
  - Objective change – standardized measure/grading scale
  - Subjective improvement
    - QOL, Visual score
    - Needs to be blinded if possible
- Durability critical
  - At least 2 years of follow-up
Peripheral lipoatrophy

- **Entry criteria**
  - Subjective entry – patient and doctor agree
- **Baseline measurement**
  - Objective - DXA, CT
- **Response**
  - % change from baseline
  - If severe LA, small amount increase enough (10-15%), especially if also metabolic improvement
  - Moderate LA, need substantial improvement (e.g. 40% over 2 yrs), but that alone may be sufficient
  - Subjective assessment if improvement slow may be problem
  - Does not worsen fat gain
Visceral fat Gain

- Entry criteria
  - Anthropometry, WC and WHR
    - Adjusted by gender

- Baseline measurement
  - objective - CT +/- DEXA
  - QOL

- Response
  - % change from baseline – 8-10% decrease in VAT
  - Lipoatrophy does not worsen
  - Metabolic changes at least neutral
  - Subjective assessment (blinded)
Dorsocervical fat pad

- Entry criteria
  - Subjective entry – patient and doctor agree

- Baseline measurement
  - Anthropomorphic measurement
  - Symptom score (specific)

- Response
  - % change from baseline
  - Subjective assessment, QOL, symptom score
All studies

- Safety issues
  - Long-term and short-term
- Impact on HIV and ART
  - No effect on VL or CD4
  - Drug interaction data on commonly used ART
Participants

Herbert Lerner          Jacqueline Capeau
Jeff Murray            Andrew Carr
Robert Perlstein       Ben Cheng
Stephen Rhodes         Simon Collins
Kimberly Struble       David Cooper

Michael de Baar        Carl Fichtenbaum
Alex DePaoli           Carl Grunfeld
Ronald Gottschalk      Esteban Martinez
Robert Kirsch          Veronica Miller
Sharon Levy             Kathy Mulligan
Norma Muurahainen      Bob Munk
Sharon Levy             Bill Powderly
Denise Sutherland -Phillips  Peter Reiss
Morrie Schambelan